SARS-CoV-2
Cuba: crisis, blockade and changes in 2021

Luis De Jesus writes about how Cuba plans to take on 2021, looking closely at the new ambitious economic development strategy “the Ordering Task”

One year of COVID-19: The known and the unknown

The global response to the COVID-19 pandemic in terms of developing a vaccine has been unprecedented. However, there is still a lot to be understood about the disease and the virus which causes

How dangerous is the new COVID-19 strain?

Immunologist Dr. Satyajit Rath talks about reports of a strain of COVID-19 from the UK, the transmission rate and its implications on public health policy

COVID-19 reinfection: Virus could hide itself in human chromosome, finds new study

The novel coronavirus can integrate its genetic material or RNA into human chromosome and reproduce itself, the study suggests

COVID-19 vaccine: Rich countries might gain, poor ones might suffer

As trials for vaccine candidates continue, the question of which countries will gain access to it has become pressing. Low-income countries are likely to suffer in this regard

COVID-19: What we know about asymptomatic patients so far

Are asymptomatic people the real drivers of COVID-19 progression? Researchers are divided as more studies arrive that further complicate the question

COVID-19: Study suggests immunity against SARS-CoV-2 could last for six months

The study analyzed the immune memory against the virus in 185 patients who had recovered from COVID-19. These included patients who were asymptomatic and those who exhibited severe clinical symptoms

Winter is coming in the Northern Hemisphere. Will COVID-19 get worse?

There is not enough data to conclusively predict if the onset of winter will lead to a greater spread of the infection. However, researchers have been studying the possibility through a variety of ways

WHO mega trial results out: Remdesivir, Interferon fail to prove effective

None of the four drug/drug combinations that were deployed in the WHO’s SOLIDARITY trial were found to be effective in reducing mortality, not even the much-hyped anti-viral drug Remdesivir

Understanding India’s low COVID-19 death rate

Contrary to the Narendra Modi government’s claims, India’s low case fatality rate in the COVID-19 pandemic is not because of any well-thought out strategy. It is rather due to a relatively young population and some statistical tricks

COVID 19: For how long do antibodies stay?

Dr. Satyajit Rath talks about the immunity developed in recovered COVID-19 patients and also the immunity that the potential vaccines can induce.

More evidence emerges of T Cell Immunity against novel Coronavirus in unexposed people

Candidate vaccines which have shown promising results have all reported trying to elicit a T cell immune response along with antibody production

    × To Subscribe